Aller au contenu principal
Accès ouvert déclaré 2025 article

Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis

18Citations signalées, ce qui n’est pas une note de qualité
54Institutions déclarées
14Pays d’affiliation déclarés

Rattachement africain : us, de, ch, sk, ca, se, it, es, nl, dk, at, fr, pl, gr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND AND OBJECTIVES: Biologically informative markers like glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) may help predict confirmed disability worsening (CDW) in multiple sclerosis (MS). However, data on the prognostic value of their blood concentrations in progressive MS (PMS) are limited, and there are substantial discrepancies in the published literature. This international collaboration uses individual participant data to define the prognostic value of serum GFAP and NfL in people with PMS (pwPMS). METHODS: Data were collected from BioMS-eu network centres and collaborating cohorts. pwPMS with primary progressive MS (PPMS) or secondary progressive MS (SPMS) with at least one GFAP value and at least three follow-up expanded disability status scale (EDSS) scores were included. The prognostic value of serum GFAP and NfL age- and sex-adjusted Z-scores for future CDW was evaluated using Cox regression models, accounting for sex, age, baseline disease duration and EDSS, and dominant treatment during follow-up. RESULTS: 1058 participants and 7530 encounters were included (median age 53 years (IQR: 44 to 59), 57% female, follow-up 4.6 years (2.9 to 8.4)) with median baseline GFAP of 0.74 (-0.10 to 1.55) and NfL of 0.64 (-0.36 to 1.51). 723 CDW events were recorded. Each GFAP Z-score increase was associated with ~10% higher CDW risk (adjusted HR (aHR) 1.107 (1.001 to 1.225), p=0.049). Results were mainly driven by SPMS participants (n=613, aHR 1.242 (1.073 to 1.438), p=0.004). Higher NfL Z-scores predicted CDW only in PPMS participants (1.236 (1.092 to 1.399), p=0.001). CONCLUSIONS: GFAP was a prognostic indicator for future CDW in pwPMS, especially in pwSPMS. On the other hand, NfL was predictive of CDW only in pwPPMS.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis
Date Crossref
12/06/2025
Éditeur
BMJ
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

University of California, San FranciscoUniversität UlmUniversity Hospital of BaselDepartment of Biomedicine BaselKantonsspital AarauInstitute of Neuroimmunology of the Slovak Academy of SciencesUniversity of LausanneUniversity of BernUniversity Hospital of BernLaboratory for Biomedical NeurosciencesUniversità della Svizzera italianaUniversity of St.GallenUniversity of ZurichUniversity Hospital ZurichBrigham and Women's HospitalHarvard UniversityMassachusetts General HospitalInstitut für Klinische NeuroimmunologieLudwig-Maximilians-Universität MünchenMedizinische Hochschule HannoverHertie Institute for Clinical Brain ResearchUniversity of TübingenSt. Josef-HospitalRuhr University BochumUniversity of RostockUniversitätsklinikum WürzburgMontreal Neurological Institute and HospitalMcGill University Health CentreOttawa HospitalKarolinska University HospitalKarolinska InstitutetAzienda Ospedaliero-Universitaria di ModenaUniversity of Modena and Reggio EmiliaUniversity of VeronaUniversitat Autònoma de BarcelonaInstituto de Salud Carlos IIIBiomedical Research Networking Center on Neurodegenerative DiseasesVall d'Hebron Institut de RecercaAmsterdam NeuroscienceAmsterdam University Medical CentersUniversity of AmsterdamMunich Cluster for Systems NeurologyTechnical University of MunichDanish Multiple Sclerosis CenterInstituto de Investigación Sanitaria del Hospital Clínico San CarlosInnsbruck Medical UniversityUniversité de NîmesMedical University of LublinNational and Kapodistrian University of AthensUniversity General Hospital AttikonUniversity of GenoaUniversity of North Carolina at Chapel HillMedical University of GrazCenter For Biomarker Research In Medicine

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Multiple Sclerosis Research StudiesAmyotrophic Lateral Sclerosis ResearchPeripheral Neuropathies and Disorders

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.